Mountain View

Inworld AI Announces $7 Million in Seed Funding from Kleiner Perkins, CRV and Meta for Metaverse AI Development Platform

Retrieved on: 
Monday, November 8, 2021
Cloud, API.AI, Fortnite, Ecosystem, DeepMind, Human, Non-player character, CEO, Technology, NASA RealWorld-InWorld Engineering Design Challenge, Kleiner Perkins, Machine learning, Specialization, Video game, CTO, Acquisition, Environment, Awareness, GLOBE, Meta, CRV, City centre, Video game console, Mobile phone, Online shopping, Copper

Inworld AI is a platform for building AI-based virtual people (and other characters) as native and engaging inhabitants within immersive realities.

Key Points: 
  • Inworld AI is a platform for building AI-based virtual people (and other characters) as native and engaging inhabitants within immersive realities.
  • Inworld AI is founded by the leadership team behind API.AI (renamed to Dialogflow following its acquisition by Google).
  • Virtual human agents created with the Inworld AI platform provide brands and developers with instant scalability and presence for populating immersive realities.
  • Inworld AI provides a developer platform for creating AI-powered virtual human agents to populate immersive realities including the metaverse, VR/AR, games, and virtual worlds.

IGM Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference

Retrieved on: 
Monday, November 8, 2021
EST, Webcast, Immunoglobulin G, Immunoglobulin M, IGM, Nasdaq, Conference, GLOBE, Vaccine

MOUNTAIN VIEW, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 2:00 p.m. EST.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 2:00 p.m. EST.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.
  • Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.
  • Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting

Retrieved on: 
Saturday, November 6, 2021
Transfer, Safety, IRIX, NASDAQ, Ophthalmology, TLT, Probe, Diabetic retinopathy, AAO, American Academy, Retina, Laser, GLOBE, American Academy of Ophthalmology, Physician, Continuous wave, Medicine, Medical device

MOUNTAIN VIEW, Calif., Nov. 06, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces that an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy and their conclusions for proper dosing and patient selection on November 6 at 10:00am PT/ 1:00pm ET. In the live discussion, attendees will learn recommendations for treatment optimization and settings with the MicroPulse P3® Probe, understand the concept of fluence and the importance of sweep speed, as well as identify the clinical drivers for patient selection, outcomes, and safety.

Key Points: 
  • Nineteen laser experts, including Robert J. Noecker, MD; Brian A. Francis, MD; Sam E. Mansour, MD; and Nathan Radcliffe, MD, will be available to discuss experiences, surgical pearls and best practices.
  • To find out specific times and available experts, visit https://www.iridex.com/aao
    Two Iridex glaucoma procedures, MicroPulse Transscleral Laser Therapy and Continuous Wave Transscleral Cyclophotocoagulation, will be featured in one of AAO's Skills Transfer Labs.
  • The title of the course is "Lasers in Glaucoma," and its director will be Lisa S. Gamell, MD.
  • This course is part of the AAO program; participation requires an AAO registration.

AMPLY Power Launches New Containerized EV Charging Infrastructure Solution, Anaheim Transportation Network Signed on as First Customer

Retrieved on: 
Friday, November 5, 2021
OMEGA, Capsule, Maintenance, ATN, Industry, CMS, Entrepreneurship, Power purchase agreement, CEO, EVS, Goal, Running, Kilowatt-hour, Anaheim Resort Transportation, Beb, Partnership, Twitter, EV, Trust, GLOBE, California Energy Commission, LinkedIn, Solution, Transport, Time, Renewable energy

MOUNTAIN VIEW, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- To offer enhanced flexibility for its customers fleet charging operations, AMPLY Power is announcing INRUSH , an innovative containerized infrastructure system for EV charging.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- To offer enhanced flexibility for its customers fleet charging operations, AMPLY Power is announcing INRUSH , an innovative containerized infrastructure system for EV charging.
  • The first deployment of this customer-ready solution is occurring with AMPLYs long-standing customer, the Anaheim Transportation Network (ATN) .
  • INRUSH is the first ready-to-deploy solution in the industry that leverages the flexibility and affordability of modular container infrastructure, said Vic Shao, Co-Founder and CEO of AMPLY Power.
  • This offering significantly reduces the time and resources required to get fleet charging facilities up and running, a key barrier to EV adoption.

IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 4, 2021

MOUNTAIN VIEW, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent developments.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent developments.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.
  • Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.
  • Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)

Retrieved on: 
Thursday, November 4, 2021

Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events.

Key Points: 
  • Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events.
  • Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for six months and as clinically indicated thereafter.
  • Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including one serious event requiring hospitalization.
  • If patients develop HBV reactivation, immediately discontinue TAVNEOS and concomitant therapies associated with HBV reactivation, and consult with experts before resuming.

Fogarty Innovation Graduate Raydiant Oximetry Raises $5 Million in Oversubscribed Series A2 Financing Round to Support Clinical Study

Retrieved on: 
Tuesday, November 2, 2021
Linda, Serie A2, Pregnancy, MD, Technology, University, SAN, Hospital, Mother, Industry, NIH, Metabolic acidosis, Child, PMID, FDA, UTMB, Band of Angels, Pulse oximetry, Government, Fetal distress, Physician, Trial of the century, CEO, Maternal–fetal medicine, Health, Fetal monitoring, Howard Brody, GLOBE, Sale, Medical imaging

MOUNTAIN VIEW, Calif. and SAN RAMON, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Fogarty Innovation , a nonprofit educational incubator for medical technology companies, announced today that its graduate, Raydiant Oximetry, Inc ., has raised an oversubscribed round of $5 million Series A2 financing.

Key Points: 
  • MOUNTAIN VIEW, Calif. and SAN RAMON, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Fogarty Innovation , a nonprofit educational incubator for medical technology companies, announced today that its graduate, Raydiant Oximetry, Inc ., has raised an oversubscribed round of $5 million Series A2 financing.
  • Raydiant Oximetry is a clinical-stage medical device company focused on improving womens and neonatal health.
  • Its innovation is LUMERAH, the first-of-its-kind non-invasive fetal oximeter designed to more accurately detect fetal distress during labor and delivery.
  • Raydiant Oximetry plans to use the proceeds of the Series A2 financing to complete a clinical study at the University of Texas Medical Branch (UTMB) in Galveston, Texas.

ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021

Retrieved on: 
Tuesday, November 2, 2021
Cancer, Domestic, Patient, Investor, Telephone, ID, Degenerative disease, International, Adult, Company, Webcast, Hidradenitis suppurativa, ANCA, Nasdaq, GLOBE, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021.
  • ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2021 to discuss these results and to answer questions.
  • ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
  • Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021

Retrieved on: 
Thursday, October 28, 2021
Technology, NASDAQ, IRIX, Company, Glaucoma, Ophthalmology, GLOBE, Macular edema, Retina

MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation(NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation(NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021.
  • The Companys management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m.
  • A live and archived webcast of the event will be available on the Investors section of the Companys website at: www.iridex.com .
  • Iridexis a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.

WSO2 API Manager to be Presented with 2021 API World Award in the Best in API Middleware Category

Retrieved on: 
Wednesday, October 27, 2021
API, Architecture, LinkedIn, Goal, Apache, CA, CIAM, Twitter, Organization, Software as a service, Adoption, Growth, APIM, University, GLOBE, CTO, WSO2, Fine chemical

Santa Clara, CA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- WSO2 , the leader in digital transformation technology, today announced that WSO2 API Manager has won a 2021 API Award in the Best in API Middleware category.

Key Points: 
  • Santa Clara, CA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- WSO2 , the leader in digital transformation technology, today announced that WSO2 API Manager has won a 2021 API Award in the Best in API Middleware category.
  • In awarding WSO2, the expert-led API World Advisory Board selected WSO2 API Manager based on three criteria:
    The award is being presented to WSO2 today, October 27, 2021, at the 2021 API Awards Ceremony during API World 2021 Virtual, which runs October 26 - 28, 2021.
  • Now in its tenth year, API World is the largest event for the API economy with more than 4,000 attendees.
  • "WSO2's WSO2 API Manager is helping developers and engineers to build upon the backbone of the multi-trillion-dollar market for API-driven products and services.